Introduction
Oxygen is an essential factor that controls numerous developmental processes and normal tissue homeostasis. At a cellular level, oxygen is required for oxidative metabolism, energy supply through the generation of ATP and cell survival [1] . In solid tumours, regions of low oxygen (hypoxia) occur as a result of a high metabolic demand and inadequate oxygen supply. The abnormally formed/inefficient vasculature found in tumours is one of the primary causes of this imbalance between oxygen delivery and consumption [2, 3] . The presence of hypoxic regions in tumours is clinically significant as they lead to resistance to therapy, genomic instability and an increase in the invasion and metastatic potential [4, 5] . Hypoxia-driven genomic instability has been attributed, in part, to the repression of the DNA repair pathways, including homologous recombination (HR) and base excision repair, observed in these conditions [6] [7] [8] [9] . A gradient of oxygen tensions occurs throughout tumours, reaching near anoxia in areas adjacent to necrotic regions. These extremely low oxygen tensions (< 0.1% O 2 ) are often referred to as radiobiological hypoxia and have been associated with the induction of DNA replication stress (RS) and the subsequent activation of DNA damage response (DDR) signalling [10] [11] [12] [13] [14] . In conditions of radiobiological hypoxia, cells have increased resistance to radiation-induced DNA damage and therefore radiotherapy. Numerous in vitro studies have demonstrated that the DNA damaging effect of radiation is absolutely dependent on the presence of oxygen at the time of exposure [5, 15, 16] . In accordance with this finding, patients with more hypoxic tumours have a worse response to radiotherapy [3] . Characterising the biological response to radiobiological hypoxia, including RS and the DDR, offers opportunities to identify novel therapeutic targets to improve radiotherapy response.
Replication stress
DNA replication is one of the most important and well-regulated biological processes, which ensures that the genome will be duplicated just once per cell cycle, and that replication is complete before the initiation of mitosis [17] . The importance of the DNA replication process is highlighted by the fact that not only the sequence of events, but also the majority of proteins involved in this process are highly conserved in eukaryotes [18] . RS is defined as the slowing or stalling of replication fork progression during DNA replication and is characterised by the accumulation of long stretches of ssDNA [4] . This ssDNA is usually formed, either because the replicative helicases continue to unwind the DNA while the replicative polymerases are stalled, or because the newly synthesised DNA is degraded by the action of nucleases [19, 20] . Replication protein A (RPA) is the first responder to RS and acts by binding and stabilising the ssDNA tracks [21] . The ssDNA, once coated with RPA, creates a primertemplate structure that serves as a signalling platform for the activation of the RS response ( Fig. 1) [22] . Specifically, after binding to ssDNA, RPA recruits and interacts with several factors involved in the ataxiatelangiectasia and RAD3-related (ATR)-dependent DDR pathway. In brief, RPA first interacts with ATRinteracting protein (ATRIP), thereby recruiting and activating the ATR kinase at the replication fork, with additional cooperation from various stress response proteins including the Rad9-Rad1-Hus1 (9-1-1) complex, the ATR-activator TOBP1 and Ewing tumourassociated antigen ETAA1 [22] [23] [24] [25] [26] . Once activated, ATR signals through phosphorylation of downstream targets to initiate the cell cycle checkpoints and prevent cells with unreplicated DNA progressing through the cell cycle. In addition to its functions in cell cycle progression, the replication checkpoint acts locally at the replication fork. ATR is essential for preventing fork collapse. For example, SMARCAL1 (SWI/SNFrelated, matrix-associated, actin-dependent regulator of chromatin, subfamily A-like 1) is phosphorylated by ATR at replication forks and maintains fork stability [27, 28] . Signalling from the ATR kinase provides time to resolve stress, and allow the accumulation of resources such as deoxyribonucleotides (dNTPs), histones and RPA around stalled forks, in order to complete replication [29, 30] . In general, ATR-mediated fork stabilisation ensures that forks will restart and continue faithful replication once the stress has been resolved. However, some lesions can be bypassed as the replication machinery may continue replicating by repriming after the lesion [31] . This generates ssDNA gaps that are 'filled' by lesion-specific polymerases or by fork remodelling [32] . Moreover, sometimes, despite the RS response, stalled forks fail to restart and eventually collapse, resulting in double-strand break (DSB) formation. Recently, RPA exhaustion was described as a key factor in replication fork breakage. Specifically, it was proposed that the suppression of firing of dormant origins by the replication checkpoint maintains an adequate supply of RPA to ensure genomic integrity at the site of DSB [33] . DSBs which occur during RS, can be formed either by passive fork breakage or after the activation of endonucleases (such as Mus81), which cleave exposed structures (such as retained ssDNA or reversed forks) [34] . Two main pathways are responsible for the repair of the DSBs: nonhomologous end joining (NHEJ), which is error-prone and can occur throughout the cell cycle, and HR, which is error-free and occurs in the S and G 2 phases of the cell cycle [35] . In addition to ATR signalling, the DDR includes activation of two other members of the PI3KK family: the ataxia-telangiectasia mutated (ATM) and DNA-dependent protein (DNA-PK) kinases [36] . It is generally considered that the DDR activates the ATR pathway in response to RS and/or at single-stranded DNA breaks (SSBs), whereas in the event of DSBs, ATM and DNA-PK mediated cascades are the primary responders [22, 37] . Importantly, ATM acts as the principle responder to DSBs, whereas DNA-PK is activated when DSBs are repaired through the NHEJ pathway [38] . DNA-PK has recently been shown to respond to RS through phosphorylation and recruitment to the replication fork [39] . Regardless of the unique actions of the above kinases in the event of DNA damage, there is considerable crosstalk and collaboration between them. In particular, the ATR and ATM kinases share many common downstream targets and functions, and have been shown to activate each other in some cases [22] . Of note, ATM activation has also been described in the absence of DNA damage, for example in response to hypoxia, heat, hypotonic and oxidative stress, and chromatin modifiers [40, 41] .
Hypoxia-induced replication stress
The first evidence that certain levels of hypoxia lead to impaired DNA replication came from 5-bromo-2 0 -deoxyuridine (BrdU) incorporation assays, which demonstrated that in radiobiological levels of hypoxia, BrdU incorporation was significantly decreased [10] . Since this observation, the induction of RS in hypoxia has been further evidenced by the detection of specific RS-induced phosphorylation events (RPA-S33, cH2AX and CHK1-S345) and using DNA fibre analysis [42, 43] . Importantly, these more recent studies verified that hypoxia-induced RS is indeed oxygen dependent, i.e. not all levels of hypoxia lead to RS [43] . Strikingly, even prolonged exposure to hypoxia does not lead to detectable SSB or DSB formation, as visualised using the 53BP1 foci assay or comet assay [12, 13] . Perhaps not surprisingly, the ATR kinase was found to respond to hypoxia-induced RS and hypoxic cells have been shown to have increased sensitivity to ATR inhibitors [44] [45] [46] [47] . However, as previously mentioned despite the lack of detectable DNA damage, ATM is also active in hypoxic conditions as evidenced by ATM-dependent phosphorylation of both itself and downstream targets such as KAP-1 [48] . ATM activation in hypoxia occurs independently of the DSBassociated MRN complex, further confirming the lack of DNA damage in these conditions [48] . Additionally, ATM remains diffuse throughout the nucleus in hypoxia and does not form specific foci. Recently, we demonstrated that ATM activation in hypoxia is, in part, dependent on the presence of RS. Specifically, hypoxia increases heterochromatic marks including trimethylation of H3 at lysine 9 (H3K9me3), which, in combination with RS, leads to activation of ATM signalling [13] .
DNA fibre analysis has been particularly informative in characterising hypoxia-induced RS as changes in replication kinetics are visualised at the single molecule level [42] . In response to hypoxia (< 0.1% O 2 ) we observed an increase in the numbers of stalled replication forks and a decrease in new origin firing. In addition, the replication rates at ongoing forks in hypoxia showed a significant reduction but not complete abrogation [43, 49] . DNA fibre analysis in noncancer cells demonstrated that hypoxia-induced RS is not restricted to cancer cells but likely occurs in all cells [43] . The level of hypoxia in tumours is extremely dynamic due to fluctuations in blood flow as a result of blockages and aberrant structures. As a result, hypoxic regions undergo cycling hypoxia, which includes periods of reoxygenation [50] . This knowledge led us to ask what would happen to DNA replication in cells experiencing hypoxia-induced RS once oxygen was restored. DNA replication can restart in response to reoxygenation, but this is dependent on how long cells experienced hypoxia-induced RS before reoxygenation. Relatively short periods of hypoxia (8 h) followed by reoxygenation allow restart of replication forks, whereas after longer periods (> 12 h) replication restart does not occur [14, 43] (Fig. 2) . These data suggested that prolonged hypoxia renders cells replication incompetent. A number of genes involved in DNA replication and repair have been found to be repressed in hypoxic conditions including members of the minichromosome maintenance complex (MCM) family [51, 52] . The MCM2-7 complex is loaded onto chromatin in the G 1 phase of the cell cycle and provides the essential helicase activity necessary for duplex unwinding during replication [20] . MCM3, MCM4 and MCM5 were all repressed at the transcriptional level in response to hypoxia and most importantly, several members of this complex, MCM5, MCM6 and MCM7, were all shown to dissociate from chromatin after prolonged exposure to hypoxia [14, 43, 53] . Once the MCM complex is removed from the chromatin in S phase it cannot be reloaded in this phase and therefore DNA replication cannot continue/restart. These data led to the hypothesis that cells that have experienced hypoxia-induced RS for prolonged periods of time (> 12 h) cannot restart replication due to disassembly of the replisome [43] . However, this hypothesis is challenging to verify experimentally as it would require the re-expression of numerous factors in hypoxic conditions.
Since the somewhat surprising finding that ATM is activated in response to hypoxia-induced RS it has also been linked to DNA replication in hypoxic conditions [40, 48] . Inhibition/depletion of ATM in hypoxia leads to slower replication rates and the accumulation of DNA damage in S phase, suggesting that the role of hypoxia-induced ATM activity is to promote replication by protecting replication fork stability [13] . Interestingly, inhibition of ATM was found to increase origin firing and in all likelihood, this is due to increased firing of dormant origins. Pharmacologic inhibition of Chk1 had no hypoxia-specific effect on DNA replication, although a significant increase in origin firing was observed after reoxygenation when Chk1 was inhibited [43] . siRNA-mediated knockdown of Chk2, however, had no effect on origin firing following reoxygenation-induced replication restart [54] . Similarly, replication restart following reoxygenation was not altered by ATM inhibition [13] .
The source of RS in hypoxianucleotide imbalance
Previous studies suggested that nucleotide imbalance might be significant in hypoxic conditions leading us to hypothesis that this might be the cause of RS [14, 22, 43] . The biosynthesis of dNTPs involves both de novo and salvage pathways. In both cases, the first step of nucleotide biosynthesis requires the action of ribonucleotide reductase (RNR). RNR is an enzyme consisting of two homodimeric subunits, RRM1 and RRM2 or RRM2B, which are encoded by three genes on different chromosomes. The RRM1 dimer constitutes the large a subunit, which contains the catalytic site, whereas the b subunit is encoded by either RRM2 or RRM2B. Importantly, the b subunit contains an oxygen-requiring di-iron tyrosyl radical site essential for catalysis. The importance of RNR is further emphasised by the many different levels of regulation, including allosteric and transcriptional control, cell cycle specific proteolysis in mammalian cells and inhibition through small proteins in yeast [55] . A critical difference between RRM2 and RRM2B is that the expression of RRM2 is tightly cell cycle regulated. Unlike RRM2B, RRM2 contains a KEN box in the N terminus of the protein, which is recognised by SCF and APC complexes, leading to RRM2 cell cycle specific degradation [56, 57] . Interestingly, an ATRdependent downregulation of cyclin F has been shown to increase RRM2 stability in response to DNA damage [57] . The RRM1/RRM2 holoenzyme is mostly responsible for providing dNTPs for S phase DNA replication and repair in proliferating cells [55] . In contrast, the RRM1/RRM2B holoenzyme is believed to generate dNTPs for DNA repair in quiescent cells, as well as for mtDNA replication [58] [59] [60] [61] . Importantly, humans with RRM2B mutations have mitochondrial diseases, including mtDNA depletion syndrome, mitochondrial neurogastrointestinal encephalopathy and autosomal-dominant progressive external ophthalmoplegia [62] [63] [64] . Interestingly, mice lacking RRM2B are not embryonic lethal, but die early after weaning due to renal failure after attenuation of the dNTP pools and increased apoptosis [65] .
Recently, we demonstrated that RNR switches isoforms from RRM2 to RRM2B allowing ongoing replication in hypoxic conditions [49, 66] . The functional activity of RNR in hypoxia is retained through increased oxygen-entering frequency and increased stabilisation of the tyrosyl radical in the RRM2B subunit. This activity of RNR allows for the preservation of fork integrity through maintaining replication rates albeit significantly slower. Inhibition of RRM2B in cells experiencing hypoxia results in detrimental consequences for cell fate and loss of RRM2B in a xenograft model showed delayed tumour growth and increased radiosensitivity, highlighting the biological importance of the hypoxic induction of RRM2B [49] . However, due to the low activity of the RRM1/ RRM2B enzyme, insufficient dNTPs are generated to maintain replication at the rates observed in normoxic conditions, explaining the occurrence of RS in hypoxia (Fig. 3 ). RRM2B transcriptional induction was shown to be p53-dependent and -independent of the hypoxiainducible factor 1a. However, it is important to note that a reduced but still apparent hypoxic induction of RRM2B protein levels was observed in p53-deficient cells, suggesting additional p53-independent mechanisms of RRM2B stabilisation in hypoxia. Interestingly, it has been shown that ATM is capable of stabilising RRM2B through direct phosphorylation at serine 72, which inhibits hyperubiquitination and degradation by the E3 ubiquitin-protein ligase, mouse double minute 2 homolog (MDM2) [67] . Given that MDM2 expression is decreased in hypoxia, this may also contribute to the stabilisation of RRM2B under these conditions [68] . Moreover, nitric oxide, which is reported to be elevated in hypoxia, has been shown to increase RRM2B in p53-deficient cells [69] . Since all these mechanisms are relevant to hypoxic stress, further investigation is needed to verify if they could be responsible for the p53-independent RRM2B induction in hypoxia. Of note, the basal levels of RRM2B expression show no significant association with p53 status [70] . Since p53 is often mutated or deleted in human tumours, the involvement of mechanisms that lead to p53-independent basal expression of RRM2B, as well as protein stabilisation under hypoxia, suggest that RRM2B can perform its hypoxic role even in the absence of functional p53 [71] . The existence of alternative mechanisms that lead to RRM2B overexpression and stabilisation in hypoxia again highlights the importance of RRM2B protein in these conditions.
RRM2B as a clinical target
Ribonucleotide reductase activity is highly associated with cancer growth rates, and overexpression of the RNR subunits has in turn been correlated with many cancer types [72, 73] . RRM2B typically showed gains in many different cancers including breast, colon, ovarian, prostate and uterine cancers as well as glioblastoma [72] . The copy number changes correlated with increased RRM2B expression in breast and prostate cancers, which supports a potential role for RRM2B as a tumour promoter [72] . In the same TCGA study, RRM2 and RRM1 showed low and rare copy number changes, respectively, in the malignancies examined. RNR has long been recognised as an important target for anticancer therapy [74] . Small-molecule inhibitors that target RNR can be classified into two categories depending on which subunit they target. Nucleoside analogues are used to target the a subunit (RRM1), as it is the subunit responsible for nucleotide binding, whereas redox active metal chelators target the b subunit (RRM2 and RRM2B) by inhibiting tyrosyl radical formation [72] . A well-known RNR inhibitor, Fig. 3 . Hypoxic conditions lead to replication stress. Nucleotide levels rapidly decrease in response to hypoxia (< 0.1% O 2 ) due to the oxygen dependency of the RNR enzyme. A RS response is then induced. RS initiates activation of the ATM and ATR kinases to coordinate the hypoxic DDR albeit in the absence of detectable DNA damage. The isoform switch and activity of RRM1/RRM2B allows for replication rates to continue at significantly reduced rates.
hydroxyurea (HU) inhibits the reduction of nucleoside diphosphates to dNDPs by scavenging the iron from the tyrosyl radical site, which is involved in RNR catalytic function. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), also known as triapine, represents a far more specific and potent inhibitor of RNR by also targeting the tyrosyl radical site of the b subunit. Interestingly, hypoxic cells treated with either HU or 3-AP showed significant loss of viability compared to untreated cells (K. Purshouse, I. P. Foskolou, E. M. Hammond unpublished data). These data suggest that targeting RNR activity specifically in hypoxic tumour cells might be an effective therapeutic strategy. Although designing specific RRM2B inhibitors has long been proposed [65] , the high sequence homology and the similarities in the mechanism of action with RRM2, have proven to be challenging obstacles. Interestingly, new approaches such as genetic strategies offer promising avenues for future drug development; for example delivery of siRNA against RRM2 by phosphorothionate oligodeoxynucleotides (GTI-2040) is in clinical trials for various solid tumours [75] [76] [77] [78] .
Conclusion
The activation of RS and the DDR is associated with the early stages of cancer development; hypoxia is a physiologically relevant factor proposed to contribute to this [79, 80] . Hypoxia-induced RS leads to activation of the DDR pathway, including ATR and ATM signalling and this occurs in the absence of detectable DNA damage and reduced DNA repair capacity [4] . These findings suggest that the initiation of the DDR in response to hypoxia-induced RS is an effective way of protecting replication forks and avoiding further genomic instability. Inhibition of key components of the RS and DDR pathways, for example ATR, Chk1 and ATM, leads to the accumulation of DNA damage in hypoxia [53] . Although the sources of hypoxia-induced RS are likely multifactorial, the oxygen dependency of RNR is a key contributing factor [34] . Targeting RNR activity specifically in hypoxic tumour cells might be an effective therapeutic strategy in combination with radiotherapy. 13 
